Only recently, we were able to show that single Stabilin inhibition reduces atherosclerosis development (Manta et al., 2022), furthermore, anti‐Stab1 antibodies are in initial clinical trials as an immunomodulatory cancer treatment (Virtakoivu et al., 2021). This evidence concerns the gene STAB1 and cancer.